Array BioPharma Inc (ARRY)

8.67
NASDAQ : Health Care
Prev Close 8.70
Day Low/High 8.50 / 8.80
52 Wk Low/High 2.70 / 13.40
Avg Volume 3.92M
Exchange NASDAQ
Shares Outstanding 169.01M
Market Cap 1.47B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Finding Bullish and Bearish Market Reversals

Finding Bullish and Bearish Market Reversals

These stocks are showing signs of changing direction.

Biotech Premarket Movers: CytomX, Aevi, Esperion

Biotech Premarket Movers: CytomX, Aevi, Esperion

CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.

Array BioPharma Provides NEMO Update

Array BioPharma Provides NEMO Update

- NRAS-mutant melanoma NDA withdrawn based on thorough discussions with FDA and following late cycle review meeting -

PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round

PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round

Jim Cramer is bullish on PaylPal, CH Robinson Worldwide, Texas Instruments and NXP Semiconductors.

Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)

Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)

Jim Cramer highlight's Buffett's confidence in American businesses and stocks, and his critique of high fees charged by money managers.

Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More

Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More

Here are Friday's top research calls, including an upgrade for Ford and downgrades for Eaton, Altria and Ralph Lauren.

Analysts' Actions -- Air Products, Disney, Colgate-Palmolive, Noble and More

Analysts' Actions -- Air Products, Disney, Colgate-Palmolive, Noble and More

Here are Monday's top research calls, including downgrades for Air Products and Colgate-Palmolive, and upgrades for Disney and Noble.

Take-Two Interactive and Actvision Blizzard: 'Mad Money' Lightning Round

Take-Two Interactive and Actvision Blizzard: 'Mad Money' Lightning Round

Jim Cramer thinks Take-Two Interactive and Activision Blizzard have winning potential.

Buy 'Trump Stocks' on Any Market-Induced Weakness: Cramer's 'Mad Money' Recap (Friday 1/20/17)

Buy 'Trump Stocks' on Any Market-Induced Weakness: Cramer's 'Mad Money' Recap (Friday 1/20/17)

The idea of buying American and hiring American is good news for defense, ag and energy stocks, says Jim Cramer.

Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018

Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018

The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.

'Mad Money' Lightning Round: Jim Cramer Focuses on Airline, Bank Stocks

'Mad Money' Lightning Round: Jim Cramer Focuses on Airline, Bank Stocks

Alaska Air is 'among the best,' says Jim Cramer; he also likes Southwest.

Jim Cramer's 'Mad Money' Recap: Don't Miss This Rotation Back Into the Nasdaq

Jim Cramer's 'Mad Money' Recap: Don't Miss This Rotation Back Into the Nasdaq

How did these technology stocks suddenly get their groove back? asks Jim Cramer.

The Market Offers Some Opportunities but They're Disappearing Fast

The Market Offers Some Opportunities but They're Disappearing Fast

The market isn't buying that Trump is bad for business

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.

Shark Bites: Market Responds With 'Deutsche Who?'

Report of settlement turns the market.

Array BioPharma (ARRY) Stock Up, JPMorgan Raises Price Target on Drug Success

Array BioPharma (ARRY) Stock Up, JPMorgan Raises Price Target on Drug Success

Following the success of Array BioPharma's (ARRY) melanoma treatment in a clinical trial announced yesterday, JPMorgan increased its price target on the stock.

Futures Swing Into Positive Territory During Debate, Asia Lower

Futures Swing Into Positive Territory During Debate, Asia Lower

Debate switches futures into positive territory after down day on Wall Street.

Noteworthy Monday Option Activity: ARRY, LLNW, LE

Noteworthy Monday Option Activity: ARRY, LLNW, LE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Array BioPharma Inc. , where a total volume of 19,126 contracts has been traded thus far today, a contract volume which is representative of approximately 1.9 million underlying shares (given that every 1 contract represents 100 underlying shares).

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

Here's a technical look at how to trade some of the most active stocks on the market right now.

Shark Bites: Not Much Reason to Buy in This Environment

I'm even staying away from the appealing stocks.

Array BioPharma (ARRY) Stock Soars on Drug Success, Piper Jaffray Ups Price Target

Array BioPharma (ARRY) Stock Soars on Drug Success, Piper Jaffray Ups Price Target

Array BioPharma (ARRY) announced on Monday that the company's treatment for metastatic melanoma met its primary endpoint in a late-stage clinical trial.

Putting 2 Biotechs Under the Microscope

These low-dollar biotech stocks are making big moves Monday -- in opposite directions.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

First Week of ARRY November 18th Options Trading

First Week of ARRY November 18th Options Trading

Investors in Array BioPharma Inc. saw new options become available this week, for the November 18th expiration.

Array BioPharma (ARRY) Stock Advances, Price Target Raised at Jefferies

Array BioPharma (ARRY) Stock Advances, Price Target Raised at Jefferies

Jefferies upped its price target on Array BioPharma (ARRY) to $7 earlier today.

Short Interest Moves 13.5% Lower For ARRY

Short Interest Moves 13.5% Lower For ARRY

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 2,190,797 share decrease in total short interest for Array BioPharma Inc. , to 14,071,789, a decrease of 13.47% since 07/29/2016.

Interesting ARRY Put And Call Options For October 21st

Interesting ARRY Put And Call Options For October 21st

Investors in Array BioPharma Inc. saw new options begin trading today, for the October 21st expiration.